Overview

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Status:
RECRUITING

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B

Phase:

PHASE2

Details

Lead Sponsor:

Fujian Akeylink Biotechnology Co., Ltd.

Treatments:

GST-HG131